{
    "title": "Gene-Editing for Common Allergies: First Phase III Results",
    "summary": "CRISPR-based treatment for severe peanut and pollen allergies shows a 94% permanent desensitization rate in the largest clinical trial to date.",
    "date": "2027-03-01",
    "category": "Precision Med",
    "source": "Genomic Weekly",
    "url": "#",
    "content": "Detailed information about \"Gene-Editing for Common Allergies: First Phase III Results\" will be expanded soon. This article covers key developments in precision med reported by Genomic Weekly."
}